The Interaction between Collagen 1 and High Mannose Type CD133 Up‐Regulates Glutamine Transporter SLC1A5 to Promote the Tumorigenesis of Glioblastoma Stem Cells
Advanced Science · 2024
DOI: 10.1002/advs.202306715 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Yuanyan Wei und 9 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Glycoconjuates Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, …. Hauptthemen laut MEDLINE: Glioblastoma, Glioma. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Biomedical Science and Technology Support Special Project, Shanghai Natural Science Foundation.
Abstract (Originalsprache)
Targeting the niche components surrounding glioblastoma stem cells (GSCs) helps to develop more effective glioblastoma treatments. However, the mechanisms underlying the crosstalk between GSCs and microenvironment remain largely unknown. Clarifying the extracellular molecules binding to GSCs marker CD133 helps to elucidate the mechanism of the communication between GSCs and the microenvironment. Here, it is found that the extracellular domain of high mannose type CD133 physically interacts with Collagen 1 (COL1) in GSCs. COL1, mainly secreted by cancer‐associated fibroblasts, is a niche component for GSCs. COL1 enhances the interaction between CD133 and p85 and activates Akt phosphorylation. Activation of Akt pathway increases transcription factor ATF4 protein level, subsequently enhances SLC1A5‐dependent glutamine uptake and glutathione synthesis. The inhibition of CD133‐COL1 interaction or down‐regulation of SLC1A5 reduces COL1‐accelerated GSCs self‐renewal and tumorigenesis. Analysis of glioma samples reveals that the level of COL1 is correlated with histopathological grade of glioma and the expression of SLC1A5. Collectively, COL1, a niche component for GSCs, enhances the tumorigenesis of GSCs partially through CD133‐Akt‐SLC1A5 signaling axis, providing a new mechanism underlying the cross‐talk between GSCs and extracellular matrix (ECM) microenvironment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NHC Key Laboratory of Glycoconjuates Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, P. R. China.
- Division of Neurosurgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China.
- Department of Neurosurgery, Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, P. R. China.
ORCID-Profile: Jianhai Jiang
Förderung
- National Natural Science Foundation of China
- Shanghai Biomedical Science and Technology Support Special Project
- Shanghai Natural Science Foundation
- Natural Science Foundation of Shanghai Municipality
Zitieren
APA
Wei, Y., Geng, S., Si, Y., Yang, Y., Chen, Q., Huang, S., Chen, X., Xu, W., Liu, Y., & Jiang, J. (2024). The Interaction between Collagen 1 and High Mannose Type CD133 Up‐Regulates Glutamine Transporter SLC1A5 to Promote the Tumorigenesis of Glioblastoma Stem Cells. Advanced Science. https://doi.org/10.1002/advs.202306715
Vancouver
Wei Y, Geng S, Si Y, Yang Y, Chen Q, Huang S, et al. The Interaction between Collagen 1 and High Mannose Type CD133 Up‐Regulates Glutamine Transporter SLC1A5 to Promote the Tumorigenesis of Glioblastoma Stem Cells. Advanced Science. 2024. doi:10.1002/advs.202306715
BibTeX
@article{Wei2024,
author = {Wei, Yuanyan and Geng, Shuting and Si, Yu and Yang, Yuerong and Chen, Qihang and Huang, Sijing and Chen, Xiaoning and Xu, Wenlong and Liu, Yinchao and Jiang, Jianhai},
title = {The Interaction between Collagen 1 and High Mannose Type CD133 Up‐Regulates Glutamine Transporter SLC1A5 to Promote the Tumorigenesis of Glioblastoma Stem Cells},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202306715}
}
EUVIMED